Search

Your search keyword '"Egüés, Nerea"' showing total 15 results
Start Over Author "Egüés, Nerea"
15 results on '"Egüés, Nerea"'

2. Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022

Author

Martínez-Baz, Iván, primary, Trobajo-Sanmartín, Camino, additional, Miqueleiz, Ana, additional, Egüés, Nerea, additional, García Cenoz, Manuel, additional, Casado, Itziar, additional, Navascués, Ana, additional, Fernández-Huerta, Miguel, additional, Echeverría, Aitziber, additional, Guevara, Marcela, additional, Ezpeleta, Carmen, additional, and Castilla, Jesús, additional

Published
2024
Full Text
View/download PDF

5. Association between different obesity measures and the risk of stroke in the EPIC Spanish cohort

Author

Abete, Itziar, Arriola, Larraitz, Etxezarreta, Nerea, Mozo, Imanol, Moreno-Iribas, Conchi, Amiano, Pilar, Egüés, Nerea, Goyenechea, Estibaliz, de Munain, Adolfo Lopez, Martinez, Maite, Travier, Noemi, Navarro, Carmen, Chirlaque, Maria-Dolores, Tormo, Maria-Jose, Gavrila, Diana, Huerta, Jose Maria, Sánchez, María-José, Molina-Montes, Esther, Requena, Mar, Jiménez-Hernández, Maria-Dolores, Ardanaz, Eva, Barricarte, Aurelio, Quiros, Jose Ramon, Rodriguez, Laudina, and Dorronsoro, Miren

Published
2015
Full Text
View/download PDF

6. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Author

Castilla, Jesús, primary, Lecea, Óscar, additional, Martín Salas, Carmen, additional, Quílez, Delia, additional, Miqueleiz, Ana, additional, Trobajo-Sanmartín, Camino, additional, Navascués, Ana, additional, Martínez-Baz, Iván, additional, Casado, Itziar, additional, Burgui, Cristina, additional, Egüés, Nerea, additional, Ezpeleta, Guillermo, additional, and Ezpeleta, Carmen, additional

Published
2022
Full Text
View/download PDF

7. Independent Role of Severe Obesity as a Risk Factor for COVID‐19 Hospitalization: A Spanish Population‐Based Cohort Study

Author

Fresán, Ujué, Guevara, Marcela, Elía, Fernando, Albéniz, Esther, Burgui, Cristina, Castilla, Jesús, Martín, Carmen, Navascués, Ana, Portillo, María Eugenia, Polo, Isabel, Ezpeleta, Carmen, Gorricho, Javier, Ardanaz, Eva, Ascunce, Nieves, Arriazu, Maite, Barricarte, Aurelio, Barriuso, Laura, Casado, Itziar, Díaz, Jorge, Ederra, María, Egüés, Nerea, Garde, Carmen, Gómez‐Ibáñez, Carlos, García Cenoz, Manuel, García, Vega, Iriarte, Nerea, Martínez‐Baz, Iván, Moreno‐Iribas, Conchi, Sayón, Carmen, and Vidán, Juana

Subjects
Adult, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Population, Medicine (miscellaneous), 030209 endocrinology & metabolism, Body Mass Index, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Endocrinology, Risk Factors, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Poisson regression, Risk factor, Prospective cohort study, education, Pandemics, Aged, education.field_of_study, Nutrition and Dietetics, SARS-CoV-2, business.industry, Incidence, Incidence (epidemiology), COVID-19, Middle Aged, Obesity, Morbid, 3. Good health, Hospitalization, Intensive Care Units, Spain, Relative risk, Cohort, symbols, Female, business, Cohort study
Abstract

Objectives This study analyzed the association between severe obesity and coronavirus disease 2019 (COVID-19) hospitalization and severe disease. Methods The incidence of hospitalization for laboratory-confirmed COVID-19 was evaluated in a prospective population-based cohort of 433,995 persons aged 25 to 79 years in Spain during March and April of 2020. Persons with and without class 3 obesity were compared using Poisson regression to estimate the adjusted relative risk (aRR) from class 3 obesity of COVID-19 hospitalization and of severe disease (intensive care unit admission or death). Differences in the effect by age, sex, and chronic conditions were evaluated. Results Individuals with class 3 obesity had a higher risk of hospitalization (aRR = 2.20, 95% CI: 1.66-2.93) and developing severe COVID-19 (aRR = 2.30, 95% CI: 1.20-4.40). In people younger than 50 years, these effects were more pronounced (aRR = 5.02, 95% CI: 3.19-7.90 and aRR = 13.80, 95% CI: 3.11-61.17, respectively), whereas no significant effects were observed in those aged 65 to 79 years (aRR = 1.22, 95% CI: 0.70-2.12 and aRR = 1.42, 95% CI: 0.52-3.88, respectively). Sex and chronic conditions did not modify the effect of class 3 obesity in any of the outcomes. Conclusions Severe obesity is a relevant risk factor for COVID-19 hospitalization and severity in young adults, having a magnitude similar to that of aging. Tackling the current obesity pandemic could alleviate the impact of chronic and infectious diseases.

Published
2020
Full Text
View/download PDF

8. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author

Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020

Subjects
Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract

I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion

Published
2021
Full Text
View/download PDF

9. Physical Activity and Risk of Cerebrovascular Disease in the European Prospective Investigation Into Cancer and Nutrition-Spain Study

Author

Huerta, José María, Chirlaque, María-Dolores, Tormo, María-José, Gavrila, Diana, Arriola, Larraitz, Moreno-Iribas, Conchi, Amiano, Pilar, Ardanaz, Eva, Barricarte, Aurelio, Dorronsoro, Miren, Egüés, Nerea, Larrañaga, Nerea, Molina-Montes, Esther, Quirós, José Ramón, Sánchez, María-José, González, Carlos A., and Navarro, Carmen

Published
2013
Full Text
View/download PDF

10. Mortality by causes in HIV-infected adults: comparison with the general population

Author

Floristan Yugo, Irisarri Fátima, Egüés Nerea, Moreno-Iribas Conchi, Aldaz Pablo, Sola-Boneta Julio, Martínez-Artola Víctor, Sagredo Mirian, and Castilla Jesús

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background We compared mortality by cause of death in HIV-infected adults in the era of combined antiretroviral therapy with mortality in the general population in the same age and sex groups. Methods Mortality by cause of death was analyzed for the period 1999-2006 in the cohort of persons aged 20-59 years diagnosed with HIV infection and residing in Navarre (Spain). This was compared with mortality from the same causes in the general population of the same age and sex using standardized mortality ratios (SMR). Results There were 210 deaths among 1145 persons diagnosed with HIV (29.5 per 1000 person-years). About 50% of these deaths were from AIDS. Persons diagnosed with HIV infection had exceeded all-cause mortality (SMR 14.0, 95% CI 12.2 to 16.1) and non-AIDS mortality (SMR 6.9, 5.7 to 8.5). The analysis showed excess mortality from hepatic disease (SMR 69.0, 48.1 to 78.6), drug overdose or addiction (SMR 46.0, 29.2 to 69.0), suicide (SMR 9.6, 3.8 to 19.7), cancer (SMR 3.2, 1.8 to 5.1) and cardiovascular disease (SMR 3.1, 1.3 to 6.1). Mortality in HIV-infected intravenous drug users did not change significantly between the periods 1999-2002 and 2003-2006, but it declined by 56% in non-injecting drug users (P = 0.007). Conclusions Persons with HIV infection continue to have considerable excess mortality despite the availability of effective antiretroviral treatments. However, excess mortality in the HIV patients has declined since these treatments were introduced, especially in persons without a history of intravenous drug use.

Published
2011
Full Text
View/download PDF

11. Association between different obesity measures and the risk of stroke in the EPIC Spanish cohort

Author

Abete, Itziar, primary, Arriola, Larraitz, additional, Etxezarreta, Nerea, additional, Mozo, Imanol, additional, Moreno-Iribas, Conchi, additional, Amiano, Pilar, additional, Egüés, Nerea, additional, Goyenechea, Estibaliz, additional, de Munain, Adolfo Lopez, additional, Martinez, Maite, additional, Travier, Noemi, additional, Navarro, Carmen, additional, Chirlaque, Maria-Dolores, additional, Tormo, Maria-Jose, additional, Gavrila, Diana, additional, Huerta, Jose Maria, additional, Sánchez, María-José, additional, Molina-Montes, Esther, additional, Requena, Mar, additional, Jiménez-Hernández, Maria-Dolores, additional, Ardanaz, Eva, additional, Barricarte, Aurelio, additional, Quiros, Jose Ramon, additional, Rodriguez, Laudina, additional, and Dorronsoro, Miren, additional

Published
2014
Full Text
View/download PDF

13. A pilot clinical study of hair grafting in chronic leg ulcers

Author

Jiménez, Francisco, primary, Garde, Carmen, additional, Poblet, Enrique, additional, Jimeno, Begoña, additional, Ortiz, Jesús, additional, Martínez, María L., additional, Gutiérrez-Rivera, Araika, additional, Pérez-López, Virginia, additional, Etxaniz, Usue, additional, Naveda, Corina, additional, Higuera, José L., additional, Egüés, Nerea, additional, Escario, Eduardo, additional, and Izeta, Ander, additional

Published
2012
Full Text
View/download PDF

15. [Smoking and multiple sclerosis].

Author

Arruti M, Castillo-Triviño T, Egüés N, and Olascoaga J

Subjects
Disease Progression, Disease Susceptibility, Humans, Risk Factors, Multiple Sclerosis etiology, Smoking adverse effects
Abstract

Introduction: Multiple sclerosis (MS) is a complex autoimmune disease of unknown etiology, in which genetic and environmental factors interact and determine the disease susceptibility. In recent years, smoking effect has been one of the emerging environmental factors in the study of MS and has been associated with an increased susceptibility and an increase in disease progression., Aim: To review the current evidence on the role of smoking in MS., Development: The review includes an update of studies that have analyzed different aspects of tobacco in MS, including the potential pathogenic pathways involved, association of smoking and risk of MS, interactions with other risk factors and the effect of smoking in the disease course., Conclusions: Observational studies show that smoking significantly increases the risk of MS (odds ratio~1.5) and is an independent risk factor. However, MS is a complex disease and this risk may be modified depending on the interaction with other genetic and environmental factors. The role of smoking as a progression factor is more controversial, with confronted results and highly variable studies, making it difficult to draw any conclusion. The mechanisms by which smoking may modify the risk and progression of the disease have to be further investigated.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results